| scholarly article | Q13442814 |
| P50 | author | Chris Twelves | Q47067174 |
| P2093 | author name string | J Marshall | |
| J Maroun | |||
| J Cassidy | |||
| U Graeven | |||
| E Van Cutsem | |||
| M Boyer | |||
| P Hoff | |||
| R L Schilsky | |||
| R Rosso | |||
| E Bajetta | |||
| B Osterwalder | |||
| P Rougier | |||
| R Bugat | |||
| A Garin | |||
| U Burger | |||
| G Pérez-Manga | |||
| Capecitabine Colorectal Cancer Study Group | |||
| J McKendric | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| capecitabine | Q420207 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 566-575 | |
| P577 | publication date | 2002-04-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin | |
| P478 | volume | 13 |
| Q33425826 | A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer |
| Q34334959 | A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors |
| Q90481360 | A Study of the S-1 or Capecitabine as First-line Regimen in Patients with Metastatic Colorectal Cancer: A Real World Study |
| Q28652720 | A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS |
| Q37225701 | A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer |
| Q36616386 | A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours |
| Q36694899 | A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer |
| Q33420046 | A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer |
| Q36614036 | A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer |
| Q33366181 | A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer |
| Q57896517 | A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer |
| Q36614004 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer |
| Q36671560 | A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer |
| Q45023409 | A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. |
| Q46902871 | A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix |
| Q46847847 | A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer |
| Q36858273 | A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer |
| Q34609932 | A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction |
| Q53650086 | A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis. |
| Q47291560 | A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population |
| Q36192043 | Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge |
| Q37270640 | Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice |
| Q37029891 | Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study |
| Q35202155 | Adjuvant therapy for rectal cancer--the transatlantic view |
| Q46502244 | Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy |
| Q38363625 | An exploratory study to identify risk factors for the development of capecitabine-induced Palmar Plantar Erythrodysesthesia (PPE). |
| Q42406916 | An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity? |
| Q80496977 | Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer |
| Q88867253 | Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer |
| Q42243044 | Balancing the efficacy and toxicity of chemotherapy in colorectal cancer |
| Q46933040 | Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experiences |
| Q38617495 | Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer |
| Q36611697 | Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. |
| Q36792721 | Candidate mechanisms for capecitabine-related hand-foot syndrome |
| Q33393811 | Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy |
| Q37122339 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients |
| Q35819857 | Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. |
| Q37077342 | Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. |
| Q38825147 | Capecitabine for treating head and neck cancer |
| Q44323778 | Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma |
| Q37400585 | Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group |
| Q33361603 | Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial |
| Q34236005 | Capecitabine in gastric cancer |
| Q36429425 | Capecitabine in the treatment of colorectal cancer |
| Q44176817 | Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience |
| Q41186022 | Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled trials |
| Q34639725 | Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials |
| Q37085987 | Capecitabine plus oxaliplatin for the treatment of colorectal cancer. |
| Q34632080 | Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy |
| Q36957572 | Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review |
| Q43260575 | Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer |
| Q53569593 | Capecitabine-induced headache responding to diltiazem. |
| Q46496664 | Capecitabine-induced oromandibular dystonia: a case report and literature review. |
| Q86087703 | Capecitabine-induced terminal ileitis |
| Q45174619 | Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule |
| Q34494672 | Chemotherapy for colorectal cancer |
| Q37602291 | Chemotherapy, which drugs and when |
| Q80477531 | Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes |
| Q24611758 | Clinical management of localized colon cancer with capecitabine |
| Q35039124 | Colorectal cancer in the elderly: is palliative chemotherapy of value? |
| Q35875388 | Combined modality therapy for rectal cancer. |
| Q35083334 | Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis |
| Q37485627 | Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy |
| Q39063211 | Concurrent capecitabine and upper abdominal radiation therapy is well tolerated |
| Q37269696 | Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials |
| Q43296470 | Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan. |
| Q46132535 | Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer |
| Q45268020 | Costs of treatment of colorectal cancer in different settings in Germany |
| Q92242538 | Current Treatment Strategies for Elderly Patients with Metastatic Colon Cancer |
| Q36960766 | Current and emerging trends in the treatment of early-stage colorectal cancer: importance of a multidisciplinary approach |
| Q30244769 | Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer |
| Q36936972 | Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience |
| Q56391087 | Dose calculation of anticancer drugs |
| Q36306269 | Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting |
| Q38845891 | Drug-induced hepatotoxicity in cancer patients - implication for treatment |
| Q37729193 | Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer |
| Q37325560 | Effect of age on drug metabolism in women with breast cancer |
| Q37403462 | Emerging role of capecitabine in gastric cancer |
| Q36151475 | Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study |
| Q28534572 | Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines |
| Q43289305 | Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis |
| Q37108258 | First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer |
| Q36760297 | First-line treatment strategies for elderly patients with metastatic colorectal cancer |
| Q41844636 | Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report |
| Q35919188 | Hypokalemia secondary to capecitabine: a hidden toxicity? |
| Q33825180 | Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses |
| Q40997435 | Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104. |
| Q37355866 | Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer. |
| Q100455599 | Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity - What are the options? |
| Q35620769 | Integrating oxaliplatin and capecitabine in adjuvant therapy of high-risk colorectal cancer |
| Q92356857 | Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment |
| Q24235217 | Interventions for preventing oral mucositis for patients with cancer receiving treatment |
| Q24235482 | Interventions for preventing oral mucositis for patients with cancer receiving treatment |
| Q24243046 | Interventions for preventing oral mucositis for patients with cancer receiving treatment |
| Q24246310 | Interventions for preventing oral mucositis for patients with cancer receiving treatment |
| Q37355937 | Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective |
| Q37339474 | Long-term oncologic outcomes of neoadjuvant concurrent chemoradiotherapy with capecitabine and radical surgery in locally advanced rectal cancer: 10-year experiences at a single institution |
| Q34202729 | Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer |
| Q35733020 | Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial |
| Q33967458 | Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma |
| Q27026129 | Management of locally advanced and metastatic colon cancer in elderly patients |
| Q38032558 | Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review). |
| Q36920617 | Metastatic colorectal cancer: current systemic treatment options. |
| Q35623320 | Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer |
| Q92592439 | Modulation of capecitabine administration to improve continuity of adjuvant chemotherapy for patients with colorectal cancer: A phase II study |
| Q64071667 | Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients |
| Q34500981 | Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study |
| Q34006430 | Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study |
| Q35741932 | New systemic frontline treatment for metastatic colorectal carcinoma |
| Q37875058 | Optimal management of metastatic colorectal cancer: current status |
| Q44849722 | Oral 5-FU and digestive cancers |
| Q35615863 | Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies |
| Q30913489 | Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials |
| Q30251387 | Oral drugs in the treatment of metastatic colorectal cancer |
| Q38633004 | Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies |
| Q24239911 | Oral versus intravenous fluoropyrimidines for colorectal cancer |
| Q38650502 | Oral versus intravenous fluoropyrimidines for colorectal cancer. |
| Q46628300 | Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). |
| Q36288022 | Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. |
| Q36989058 | Palliative chemotherapy in advanced colorectal cancer patients 80 years of age and older |
| Q35444531 | Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis |
| Q30227039 | Perceptions and Experiences of Patients Receiving Oral Chemotherapy |
| Q78601142 | Pharmacoepidemiology and drug safety |
| Q38072718 | Pharmacokinetic evaluation of capecitabine in breast cancer |
| Q36201411 | Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas |
| Q36201465 | Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer |
| Q41559464 | Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. |
| Q35482173 | Phase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patients |
| Q36695781 | Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil |
| Q35638434 | Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer |
| Q36697132 | Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer |
| Q33386361 | Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer |
| Q34746009 | Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours |
| Q33370303 | Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine |
| Q34488678 | Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5 |
| Q35542484 | Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer |
| Q44067905 | Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function |
| Q58583964 | Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer |
| Q33620052 | Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer |
| Q44723860 | Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma |
| Q53374544 | Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. |
| Q89208465 | Real-World Adverse Effects of Capecitabine Toxicity in an Elderly Population |
| Q46652612 | Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial |
| Q98213026 | Regulatory CDH4 genetic variants associate with risk to develop capecitabine-induced hand-foot syndrome |
| Q25257445 | Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study |
| Q47139930 | Reversible severe fatty liver induced by capecitabine: A case report |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q40751962 | Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy. |
| Q35070531 | S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis. |
| Q55073748 | Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. |
| Q37781051 | Safety of capecitabine: a review |
| Q37337130 | Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers |
| Q44767638 | Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer |
| Q38216008 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? |
| Q36615421 | Side effects during chemotherapy predict tumour response in advanced colorectal cancer |
| Q99551807 | Significance of age-associated quality of life in patients with stage IV breast cancer who underwent endocrine therapy in Japan |
| Q36277429 | Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists |
| Q40030910 | Synchronous hepatic metastasis and metachronous Krukenberg tumor from advanced colon cancer. A case report with an unexpected disease-free survival |
| Q37345922 | Systemic and targeted therapy for advanced colon cancer |
| Q95806910 | Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma |
| Q37109507 | Systemic therapy for metastatic colorectal cancer: current questions |
| Q38059634 | Systemic treatment of gastrointestinal cancer in elderly patients |
| Q33916021 | Targeting cancers in the gastrointestinal tract: role of capecitabine |
| Q43435815 | The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience |
| Q36895084 | The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients |
| Q38842633 | Therapeutic drug monitoring of 5-fluorouracil. |
| Q80510490 | Thymidylate synthase inhibitors |
| Q37653406 | Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study |
| Q36715266 | Tolerance to chemotherapy in elderly patients with cancer |
| Q37427386 | Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer |
| Q34577462 | Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction |
| Q44457418 | Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial |
| Q26781457 | Treatment of colorectal cancer in the elderly |
| Q43125193 | Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine |
| Q49547512 | Up-regulation of miR-324-5p inhibits proliferation and invasion of colorectal cancer cells by targeting ELAVL1. |
| Q35693336 | Update on adjuvant trials in the treatment of high-risk colorectal cancer |
| Q80080404 | [Hand-foot syndrome with capecitabine therapy] |
| Q82366772 | [Management of colorectal cancer of elderly patients] |
| Q79303377 | [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer] |
Search more.